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PIK3CA is the most frequently mutated oncogene in human cancers. PIK3CA is phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha. It controls cell growth, proliferation, motility, survival, differentiation
and intracellular trafficking. In most of human cancer alteration occurred frequently in the alpha isoform of
phosphatidylinositol 3 kinase. PIK3CA mutations were most frequent in endometrial, ovarian, colorectal, breast,
cervical, squamous cell cancer of the head and neck, chondroma, thyroid carcinoma and in cancer family
syndrome. Inhibition of PI3K signaling can diminish cell proliferation, and in some circumstances, promote cell
death. Consequently, components of this pathway present attractive targets for cancer therapeutics. A number of
PI3K pathway inhibitors have been developed and used. PI3K inhibitors (both pan-PI3K and isoform-specific PI3K
inhibitors), dual PI3K-mTOR inhibitors that are catalytic site inhibitors of the p110 isoforms and mTOR (the kinase
component of both mTORC1 and mTORC2), mTOR catalytic site inhibitors, and AKT inhibitors are the most
advanced in the clinic. They are approved for the treatment of several carcinomas.Findings
PIK3 was discovered by Lewis Cantley and his colleagues
[1]. PIK3CA is phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha. The pathway, with onco-
gene PIK3CA and tumor suppressor PTEN (gene), is
implicated in insensitivity of cancer tumors to insulin and
IGF1, in calorie restriction. PIK3 controls cell growth,
proliferation, motility, survival, differentiation and intra-
cellular trafficking [2]. There are two subunits 85 kDa
regulatory subunit and a 110 kDa catalytic subunit. Gene
of PIK3 is located on chromosome 3q26.3 [3]. The
encoded protein represents the catalytic subunit, which
uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns
(4,5)P2. This gene is kinases in PI3K family. PIK3 classify
into three classes on the basis of primary structure, regula-
tion and in vitro lipid substrate specificity [4]. Class I PI3K
is responsible for cell growth, proliferation and survival. It
consists of two subclasses: Ia - dimeric components,
comprised of catalytic subunits: p110α, p110β, p110δ, as-
sociated with p85 regulatory subunit and subclass Ib,
which is heterodimers consisting of p110γ catalytic sub-
unit, connected with p101 regulatory subunit for trans-
mission of signals from receptor tyrosine kinase –RTK(i.e.* Correspondence: coolaslam8@hotmail.com
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reproduction in any medium, provided the orEGFR, PDGFR). In most of human cancers, regulation of
this signal transduction pathway is frequently disrupted by
alterations of PI3K pathway [5,6].
In most of human cancer the gene which is frequently
altered is that encodes the alpha isoform of phos-
phatidylinositol 3 kinase [6]. PIK3CA mutations were most
frequent in endometrial (21%), ovarian (17%), colorectal
(17%), breast 14%), cervical (13%), and squamous cell
cancer of the head and neck (9%) [7]. In Cloves Syndrome
mutations occur in PIK3CA gene in a range of 3-30%.
Cloves mainly caused by post zygotic activating mutation
of PIK3CA [8].
With regard to mutation frequencies, PIK3CA is the
most frequently mutated oncogene in human cancers.
Generally pik3ca gene is deregulated by PTEN gene
(tumor suppressor gene). In many tumors PTEN muta-
tion leads to hyperactivity of PIK3CA oncogene [9]. Di-
verse PIK3CA mutations activate lipid kinase activity
hence changing confirmation of cytosolic membranes.
This up regulates enzymatic activity serving as a com-
mon mutated gene in cancers.
In thyroid carcinoma PIK3 pathway is involved, and
activation of this pathway is through stimulatory mole-
cules or through loss of inhibitory molecules [10]. In
one study it is seen that PIK3CA mutation is not com-
mon rather its amplification is common and may be
mechanism in activation of PIK3/akt in some thyroidl Ltd. This is an Open Access article distributed under the terms of the Creative
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in benign thyroid adenoma (BTA), follicular thyroid can-
cer (FTC) and anaplastic thyroid cancer (ATC) and pro-
gression from BTA to FTC to ATC [11]. Mutation in
PIK3CA is also seen in the pathogenesis of thyroid
cancer relatively common in anaplastic thyroid carcin-
oma. In Middle Eastern papillary thyroid carcinoma,
synergistic effect of PIK3 and BRAF suggest their role in
tumorogensis [12].
It is proved that mutation of PIK3CA occur in signifi-
cant number of human glioblastoma multiforme [13].
Similarly high expression of PIK3CA is associated with
increased chances colorectal metastasis. PIK3CA inhibi-
tors may be beneficial in the treatment of colorectal can-
cer and decreases invasiveness of melanoma cells [14].
Cancer family Syndrome is a genetic disorder in which
genetic mutations occur in or more genes predisposed
the effected individual to the development of cancer and
may also cause the early onset of tumor [15]. Main cul-
prit in causing Cowden Syndrome is PTEN mutation
but 8 of 91(8.8%) unrelated Cowden syndrome individ-
ual without germ line mutations carries 10 germ line
PICK3CA mutation (7 missense, 1 non-sense and 2
indels) [16]. Analysis at exon 1,7,9 and 20 of the PIK3CA
gene revealed somatic mutations in 21% (8 out of 39) of
familial adenomatous polyposis invasive carcinoma, 21%
(7 out of 34) of Hereditary non polyposis colorectal inva-
sive carcinoma, 15% (8 of 52%) of sporadic invasive
carcinoma and 14% (7 out of 50) of sporadic colorectal
metastasis in liver. Mutation in Familial adenomatous
polyposis and HNPCC predominantly occur in kinase
domain (exon 20), while majority of mutations in spor-
adic cases occurred in Helical domain (exon 9) [17]. In
another study it was identified that in HNPCC, mutation
in PIK3CA was identified in 14% tumor while over ex-
pression in 59% of tumor [18].
Exon 9 and 20 of the PIK3CA gene were analyzed for
clear cell adenocarcinoma, it was found that somatic
mutations of PIK3CA gene was detected in 10/23(43%)
and in all cases the type of mutation was H1047R in the
kinase domain. Findings suggest that mutation of PIK3CA
gene occur in putative pre cursor lesion of CCA ( Clear
cell adenocarcinoma) [19].
In chondroma there is involment of 3p263-q 29 gene
causing loss of PIK3CA gene [20]. In patients of primary
endometrial carcinoma, mutation occur in PIK3CA path-
way occur in 172(16.2%) tumor, mostly they were high
grade tumor [21]. Son et al. reported that in 40% prostatic
carcinomas, PIK3CA amplification occurs in 13% and
PIK3CA mutation in 3% tumor [22].
Among patients with mutated-PIK3CA colorectal can-
cers, regular use of aspirin after diagnosis was associated
with superior colorectal cancer–specific survival and over-
all survival but In contrast, among patients with wild-typePIK3CA, regular use of aspirin after diagnosis was not as-
sociated with colorectal cancer–specific survival [23].
The prognostic markers may have another role in
predicting and guiding the clinical treatment of cancer
patients by allowing the identification of patients suited
to current therapies. In this era of molecularly targeted
therapy, inhibitors and antibodies targeting specific mol-
ecules are vigorously being developed, and some have
been demonstrated to be effective in clinical settings.
The PI3K/Akt pathway is one of the most important
signaling pathways in human carcinogenesis. Import-
antly, PIK3CA amplification could aberrantly activate
the PI3K/Akt signaling pathway. Inhibition of PI3K signal-
ing can diminish cell proliferation, and in some circum-
stances, promote cell death. Consequently, components of
this pathway present attractive targets for cancer thera-
peutics. A number of PI3K pathway inhibitors have been
developed and are being evaluated in preclinical studies
and in early clinical trials. Rapamycin analogs, such as
temsirolimus and everolimus that specifically inhibit
mTORC1 are the most advanced in the clinic, and they
are approved by Food and drug administration for the
treatment of advanced renal cell carcinoma. Other PI3K
pathway inhibitors include PI3K inhibitors (both pan-
PI3K and isoform-specific PI3K inhibitors), dual PI3K-
mTOR inhibitors that are catalytic site inhibitors of the
p110 isoforms and mTOR (the kinase component of both
mTORC1 and mTORC2), mTOR catalytic site inhibitors,
and AKT inhibitors. Not only do these agents have the
capacity to inhibit cancer cell proliferation and survival
signals as described above, but they may also impact
tumor angiogenesis, metastasis, and metabolism [2].
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